Core Viewpoint - The controversy surrounding the collagen content in the "Kefumei" product from Giant Biological has raised significant questions about product labeling and industry standards, highlighting potential discrepancies between claimed and actual ingredient levels [4][6][9]. Group 1: Allegations and Findings - Dr. Hao Yu's report claims that the actual collagen content in the "Kefumei" collagen stick is only 0.0177%, significantly below the regulatory threshold of 0.1% [1][3]. - The report also indicates that key component glycine was not detected in the product, challenging the validity of Giant Biological's claims regarding their recombinant collagen technology [3][5]. - The detection method used by Dr. Hao Yu, which includes high-precision HPLC and calibration with 18 amino acid internal standards, is said to be highly sensitive and reliable [5]. Group 2: Company Response - In response to the allegations, Giant Biological emphasized the compliance of their products with regulatory standards and stated that their internal testing showed collagen content above 0.1% [6][8]. - The company criticized the detection methods used by Dr. Hao Yu as not being recognized by industry standards and claimed that the results lacked credibility due to methodological issues [6][7]. - Giant Biological announced that they have engaged multiple third-party testing agencies to verify their product's content and will disclose results once available [6][8]. Group 3: Industry Context - The incident has highlighted a broader issue within the recombinant collagen industry, where there is currently no unified testing method or standard, leading to significant discrepancies in reported results [9]. - The ongoing debate reflects a conflict between technical standards and commercial interests, impacting consumer trust and transparency in the medical aesthetics sector [9].

Core Viewpoint - The article discusses the controversy surrounding Giant Bio (巨子生物) and its flagship product, Kefu Mei (可复美), which has been accused of potential fraud regarding its collagen content, leading to a crisis of trust among investors and consumers [1][4]. Group 1: Controversy and Market Impact - On May 24, a report from "Dr. Yan's Research Institute" claimed that Kefu Mei's collagen content was undetectable, raising questions about the company's credibility and regulatory compliance [1][4]. - Following the allegations, Giant Bio's stock price fell over 10% on May 26, closing at 73.6 HKD per share, with a total market capitalization of 788.19 billion HKD [4]. - Other companies in the collagen market, such as Jinbo Bio (锦波生物), Marubi (丸美生物), and Furuida (福瑞达), also experienced stock price declines amid the controversy [4]. Group 2: Product and Testing Disputes - The report highlighted three main issues with Kefu Mei: the claimed collagen content was only 0.0177%, below the regulatory threshold of 0.1%, and the absence of glycine, a key amino acid in collagen [9][11]. - Giant Bio defended its product, stating that it complies with national standards and has undergone multiple testing phases to ensure quality [11]. - The lack of standardized testing methods for collagen products in China has been identified as a significant issue, leading to discrepancies in test results from different institutions [12]. Group 3: Industry Context and Growth Potential - The collagen market in China reached 192.4 billion CNY in 2022, with a projected compound annual growth rate of 44.93%, expected to reach 585.7 billion CNY by 2025 [20]. - Companies like Jinbo Bio and Marubi are actively developing their collagen products, with Jinbo Bio reporting a revenue increase of 84.92% in 2024 [20][21]. - The article emphasizes the need for a scientific testing framework and transparent regulatory oversight to address the ongoing challenges in the collagen industry [17][22].

Core Viewpoint - The controversy surrounding the collagen product "Human-Like Recombinant Collagen Essence" from Giant Bio is primarily focused on the alleged discrepancy between the claimed and actual content of recombinant collagen, with accusations of misleading advertising and lack of industry standards for testing [1][4][5]. Group 1: Allegations and Responses - A blogger claimed that the actual recombinant collagen content in the product is only 0.0177%, significantly lower than advertised [1][4]. - Giant Bio responded by stating that their internal tests show collagen content above 0.1%, disputing the blogger's claims and questioning the validity of the testing methods used [1][5][6]. - The blogger criticized Giant Bio for not addressing two key scientific questions in their response and emphasized the need for transparency and accountability [2]. Group 2: Testing Standards and Methodology - The lack of established industry and national standards for testing recombinant collagen in cosmetics has led to disputes over testing methods and ingredient definitions [3][6]. - The blogger used HPLC (High-Performance Liquid Chromatography) to detect amino acid content, finding only 0.0177%, which raises questions about the product's labeling [4][10]. - Industry experts noted that the testing methods used by both parties require proper validation to ensure reliability, and the methods referenced by Giant Bio may not be directly applicable to cosmetic regulations [6][7]. Group 3: Ingredient Definition and Labeling - The core issue also revolves around how recombinant collagen is defined and whether the product contains genuine collagen, as the absence of glycine in the test results raises doubts [8][11]. - The blogger argued that the product's labeling as "soluble collagen" may mislead consumers regarding its actual collagen content, similar to how other cosmetic ingredients can be misrepresented [7][11]. - Giant Bio claimed that their product meets labeling regulations, asserting that the soluble collagen content is above 0.1% and should be listed as a primary ingredient [6][9].

成交活跃股方面，沪市港股通前十大成交活跃股中，小米集团-W成交额为33.14亿港元，成交金额居 首；其次是美团-W、阿里巴巴-W，成交金额分别为31.69亿港元、27.24亿港元。以净买卖金额统计， 美团-W净买入额为17.80亿港元，净买入金额居首，该股收盘股价下跌5.48%。净卖出金额最多的是盈 富基金，净卖出14.66亿港元，收盘股价下跌1.26%。 深市港股通前十大成交活跃股中，成交额居首的是小米集团-W，成交金额23.12亿港元；其次是美团- W、腾讯控股，成交金额分别为22.17亿港元、17.29亿港元。以净买卖金额统计，有2只股为净买入，净 买入金额最多的是地平线机器人-W，净买入7.30亿港元，该股收盘下跌6.45%。净卖出金额最多的是腾 讯控股，净卖出11.46亿港元，收盘股价下跌1.54%。（数据宝） 5月26日恒生指数下跌1.35%，报收23282.33点，全天南向资金通过港股通渠道合计净卖出15.07亿港 元。 证券时报·数据宝统计，5月26日港股通全天合计成交金额为996.72亿港元，成交净卖出15.07亿港元。 具 体来看，沪市港股通成交金额639.69亿港元，成交净买入18.56 ...

Core Viewpoint - The controversy surrounding Juzhibio's flagship product, Kefu Mei, has raised significant concerns about the authenticity of its collagen claims, leading to a crisis of trust among investors and consumers [1][3][6]. Company Summary - Juzhibio, known as a leader in recombinant collagen, has faced allegations of product falsification, particularly regarding its Kefu Mei product, which reportedly contains only 0.0177% collagen, below the regulatory threshold of 0.1% [3][4]. - The company has stated that all its products are compliant with regulatory standards and have undergone rigorous quality checks [4][6]. - Following the controversy, Juzhibio's stock price fell by 4.04% to HKD 73.6, with a total market capitalization of HKD 788.19 billion as of May 26 [2]. Industry Summary - The demand for aesthetic products, including hyaluronic acid and collagen, has been rising, with major players like Juzhibio and Jinbo Bio seeing growth despite market challenges [2][9]. - The recombinant collagen market in China is projected to grow significantly, reaching CNY 585.7 billion by 2025, with a compound annual growth rate of 44.93% [10][12]. - The lack of standardized testing methods for collagen products has led to discrepancies in product claims and consumer trust issues, highlighting the need for regulatory frameworks in the industry [5][8][12].

Core Viewpoint - The recent controversy surrounding Giant Biological (巨子生物) has led to a significant decline in its stock price and raised questions about the integrity of its flagship product, "Recombinant Collagen" [1][2][6] Company Overview - Giant Biological, established in September 2001, is a leader in the global recombinant collagen market, with a registered capital of 68,752.179 million RMB [3] - The company's product line includes "Recombinant Collagen Essence," which claims to enhance skin firmness and elasticity [3] Controversy Details - A report by Dr. Hao Yu accused Giant Biological of product fraud, stating that the collagen content in its "Recombinant Collagen Essence" was only 0.0177%, below the non-trace standard of 0.1% [3][4] - The company has strongly denied these allegations, asserting that all products undergo rigorous quality control and testing [4][5] Market Impact - Following the controversy, Giant Biological's stock price fell by over 8% on May 26, 2023, closing at 73.600 HKD, resulting in a market capitalization of 788 billion HKD [1][6] - The company's market value has decreased from 900 billion HKD to 788 billion HKD due to the ongoing scandal [7] Financial Performance - For 2024, Giant Biological is projected to have a revenue of 5.678 billion RMB, with a year-on-year growth of 56.53% [8] - The company's net profit is expected to be 2.062 billion RMB, reflecting a growth of 42.06% [8] - Despite strong revenue growth, the company's R&D expenditure is only 107 million RMB, accounting for less than 2% of its revenue [8]

智通财经APP获悉，5月26日港股市场，北水成交净卖出15.07亿港元，其中港股通(沪)成交净买入18.56 亿港元，港股通(深)成交净卖出33.63亿港元。 北水净买入最多的个股是美团-W(03690)、中国移动(00941)、地平线机器人-W(09660)。北水净卖出最 多的个股是腾讯(00700)、阿里巴巴-W(09988)、盈富基金(02800)。 | 股票名称 | 买入额 | 卖出额 | 买卖总额 | | --- | --- | --- | --- | | | | | 净流入 | | 小米集团-W | 16.57 乙 | 16.57 亿 | 33.14 乙 | | HK 01810 | | | -13.02万 | | 美团-W | 24.74 Z | 6.95亿 | 31.69 亿 | | HK 03890 | | | +17.80 乙 | | 阿里巴巴-W | 8.39亿 | 18.85 乙 | 27.24亿 | | HK 09988 | | | -10.46 Z | | 腾讯控股 | 7.79亿 | 17.25亿 | 25.04亿 | | HK 00700 | | | -9.45 Z | | 比 ...

Core Viewpoint - The ongoing dispute regarding the detection methods for recombinant collagen in cosmetics has raised significant concerns about the reliability of testing methods used by the company, Juzhi Biotechnology, and the implications for consumer trust [1][4]. Group 1: Detection Methods - Juzhi Biotechnology referenced the "Detection Methods for Recombinant Collagen Content" from the Chinese medical industry standard YY/T 1947-2025, which includes two main types of detection methods [1][2]. - The first method is the "mass spectrometry method," which is primarily used for tissue regeneration materials and is not suitable for complex cosmetic formulations due to potential interference from other ingredients [2][3]. - The second method includes six techniques, with the Kjeldahl method being the most likely choice for Juzhi Biotechnology, despite its limitations in accurately assessing specific proteins in complex formulations [2][3]. Group 2: Product Withdrawal and Consumer Trust - Juzhi Biotechnology's product, Human-Like Recombinant Collagen Essence, has been removed from major sales channels, raising questions about the company's testing results [4]. - The claim that testing for recombinant collagen content requires raw materials from Juzhi is misleading, as the product itself can be purchased for independent testing [4][5]. - The company's practice of not selling raw materials externally may pose risks, as it limits independent verification and peer review of their recombinant collagen [4][5]. Group 3: Questions and Concerns - There are significant concerns regarding the independence of any future sample testing if Juzhi Biotechnology provides the samples themselves, as this could lead to questions about the integrity of the results [5]. - Two critical questions remain unanswered by Juzhi Biotechnology: the absence of the core amino acid glycine in the tests and the potential misrepresentation of dipeptides as "mini collagen" [5].

Core Viewpoint - The stock price of Giant Bio (HK02367) experienced a significant decline following allegations of product fraud related to its brand, Kefu Mei, which led to a public statement denying the accusations and asserting compliance with regulatory standards [9][10]. Group 1: Company Performance - As of May 26, Giant Bio's stock opened with a drop exceeding 8%, later narrowing to a decline of 3.52% [1]. - The company's market capitalization is approximately 80 billion HKD [11]. - Kefu Mei, a brand under Giant Bio, reported sales revenue exceeding 4.5 billion CNY in 2024, reflecting a year-on-year growth of 62.9% [10]. Group 2: Industry Context - The A-share market saw a collective decline in stocks related to recombinant protein, with notable drops in companies such as Ruizhi Pharmaceutical and Sanofi Guojian, each falling nearly 6% [2]. - The market reaction indicates a broader concern regarding the credibility of companies in the recombinant protein sector following the allegations against Giant Bio [2].

Core Viewpoint - The article discusses the challenges faced by Juzi Biotechnology, particularly regarding allegations of product fraud and the company's heavy reliance on its flagship product, Kefu Mei, amidst increasing scrutiny and competition in the beauty and healthcare industry [1][5][7]. Company Overview - Juzi Biotechnology, founded by Fan Daidi, specializes in recombinant collagen products, with its flagship offerings being Kefu Mei and Keli Jin [1][4]. - The company went public on the Hong Kong Stock Exchange in 2022, achieving a market capitalization of approximately HKD 821 billion (RMB 753 billion) as of May 23, 2025 [4]. Financial Performance - Juzi Biotechnology reported a revenue of RMB 55.39 billion in 2024, marking a 57.17% year-on-year increase, with a net profit of RMB 20.62 billion, up 42.06% [7]. - The contribution of Kefu Mei to the company's revenue rose from 30.3% in 2019 to 82% in 2024, while the second brand, Keli Jin, decreased to 15.2% [7]. Research and Development - The company's R&D expenditure in 2024 was only RMB 1.07 billion, accounting for 1.9% of its revenue, significantly lower than competitors like Huaxi Biotechnology and Jinbo Biotechnology, which spent 7.13% and 4.92% of their revenues on R&D, respectively [8]. - Juzi Biotechnology's core patents are primarily from 2005 to 2013, indicating a slow pace of new product development [8]. Market Challenges - The company is currently facing allegations of product fraud, specifically regarding the efficacy of its recombinant collagen products, which has led to public scrutiny and potential reputational damage [5][6]. - There are concerns about the company's supply chain management and regulatory compliance, particularly following allegations of using banned ingredients in its products [7][8].